Sartorius Stedim Biotech and greenovation Biotech will work on the process-scale implementation of the latter’s technology for producing complex proteins from moss cells called bryotechnology.
The companies have been working together to develop fermentation processes in the field of bryotechnology. Yet, notes Hans-Peter Casel, managing director of Sartorius Stedim Systems, “The special requirements of the GMP environment pose real challenges to process-scale implementation of bryotechnology.”
Sartorius Stedim Biotech says that it will now work on delivering the first GMP-compliant photobioreactor for bryotechnological applications within the next few months.
Bryotechnology simplifies the process engineering involved with drug manufacturing, according to the firms. Moss cells can be cultivated using relatively simple culture medium compositions, which reduce the complexity involved in controlling the process, they explain.